ClinicalTrials.gov
ClinicalTrials.gov Menu

Characterization of High Density Lipoprotein (HDL) in Type 2 Diabetes (T2D) After Fenofibrate or Niacin Treatment (LOWHDL)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02153879
Recruitment Status : Completed
First Posted : June 3, 2014
Last Update Posted : June 3, 2014
Sponsor:
Collaborator:
Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders
Information provided by (Responsible Party):
LUIS MASANA, MD, Institut Investigacio Sanitaria Pere Virgili

Brief Summary:

The structural and functional alterations of high density lipoproteins (HDL) levels in type 2 diabetes (T2D) patients linked to hypertriglyceridemia, hyperglycemia, insulin resistance, inflammation and oxidation, play a major role in the increased macrovascular risk in these patients. An impaired function of the adipose tissue (AT) in T2D contributes to low HDL concentrations.

Objectives: 1) Quantitative and qualitative characterisation of HDL subclasses by ultracentrifugation, proteomic and metabolomic techniques. 2) To study the relationship between the HDL subclasses, preβ1 HDL and remnant HDL, and clinical determinants of arteriosclerosis. 3) Functional in vitro studies of the HDL subclasses determined in Objective 1. 4) To study the role of AT determining the low HDL levels. 5) To study the impact of HDL increasing drugs on HDL qualitative changes.


Condition or disease Intervention/treatment Phase
Type 2 Diabetes Mellitus Dyslipidemia Drug: Fenofibrate Drug: Niacin plus laropiprant Phase 4

Detailed Description:
Groups of subjects: a) Diabetic patients with low HDL; b) Non-diabetic patients with low HDL; c) Diabetic patients with normal HDL levels; and d) Non-diabetic patients with normal HDL levels. The studies will be performed after washing out lipid lowering drugs. Intima media thickness (IMT) will be performed in all groups. Main biochemical techniques will be centralised. Isolation and characterisation of HDL subclasses and remnant HDL, as well as a determination and preβ1 HDL will be performed. HDL studies examining HDL proteomic and metabolomic profiles will be performed. Functional studies will determine the effects on the endothelium, inflammation, cholesterol efflux and oxidation according the qualitative changes. These HDL measurements will be repeated in group (a), after they are treated with fibrates or Niacin. HDL metabolism in adipocytes will be extensively studied, and the clinical associations between HDL alterations and plasma AT-derived molecules will be examined.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 30 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: Qualitative and Quantitative Characterization of HDL in T2D After Fenofibrate or Niacin Treatment in Spanish Population
Study Start Date : February 2009
Actual Primary Completion Date : December 2011
Actual Study Completion Date : December 2013

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Fenofibrate
Fenofibrate 145 mg/day for 12 weeks
Drug: Fenofibrate
fenofibrate 145/day for 12 weeks
Other Name: Secalip

Experimental: Niacin plus Laropiprant
Niacin 2g/day plus Laropiprant for 12 weeks
Drug: Niacin plus laropiprant
Niacin 2 g/day plus Laropiprant for 12 weeks
Other Name: Tredaptive




Primary Outcome Measures :
  1. HDL particles size and number assessed by nuclear magnetic resonance (NMR) and reported as nm and micromol/L [ Time Frame: Two periods of 12 weeks treatment according to crossing over design ]
    HDL particles were studied by NMR in T2D patients after treatment with fenofibrate or Niacin


Secondary Outcome Measures :
  1. Apolipoprotein A1 (Apo A1), apolipoprotein A2 (Apo A2), paraoxonase (PON) HDL concentration (g/l - mg/l) [ Time Frame: Two periods of 12 weeks treatment according to crossing over design ]
    Apoprotein and antioxidant enzymes composition of HDL were also measured


Other Outcome Measures:
  1. Lecithin-cholesterol acyltransferase (LCAT) and cholesteryl ester transfer protein (CETP) activity (AU - pmol/h*μl) and mass (microg/ml) [ Time Frame: Two periods of 12 weeks treatment according to crossing over design ]
    LCAT and CETP mass and activities were measured;



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   30 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Type 2 diabetic patients
  • Age from 30 years to 70 years
  • HDL not exceeding 50 mg/dl in men or 60 mg/dl in women

Exclusion Criteria:

  • to be a smoker
  • To be diagnosed with diabetes less than three months before
  • To have triglyceride levels above 400 mg/dl
  • Glycated hemoglobin higher than 9%
  • Albuminuria above 300 mg/mg creatinine
  • Chronic kidney disease (eFGR <30 ml/min/1.73 m2)
  • Advanced retinopathy
  • Neuropathy
  • Cardiovascular disease in the last three months
  • Chronic liver insufficiency
  • Neoplastic disease or any chronic or incapacitating disease

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02153879


Locations
Spain
Hospital Universitari Sant Joan
Reus, Tarragona, Spain, 43204
Sponsors and Collaborators
Institut Investigacio Sanitaria Pere Virgili
Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders
Investigators
Study Director: Luis Masana, Professor Institut Investigacio Sanitaria Pere Virgili

Additional Information:
Responsible Party: LUIS MASANA, MD, Professor, Institut Investigacio Sanitaria Pere Virgili
ClinicalTrials.gov Identifier: NCT02153879     History of Changes
Other Study ID Numbers: IISPV-HUSJR-LOWHDL
First Posted: June 3, 2014    Key Record Dates
Last Update Posted: June 3, 2014
Last Verified: May 2014

Keywords provided by LUIS MASANA, MD, Institut Investigacio Sanitaria Pere Virgili:
HDL
Niacin
Fenofibrate
Diabetes
Metabolomics

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Dyslipidemias
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Lipid Metabolism Disorders
Fenofibrate
Niacin
Niacinamide
Nicotinic Acids
Hypolipidemic Agents
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Lipid Regulating Agents
Vasodilator Agents
Vitamin B Complex
Vitamins
Micronutrients
Growth Substances
Physiological Effects of Drugs